Global Pelvic Inflammatory Disease (PID) Treatment Supply, Demand and Key Producers, 2023-2029

Page: 112

Published Date: 02 Sep 2023

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Pelvic Inflammatory Disease (PID) Treatment market size is expected to reach $ 1120.9 million by 2029, rising at a market growth of 5.4% CAGR during the forecast period (2023-2029).

The global pelvic inflammatory disease (PID) treatment market pertains to the market for therapies and medications used in the management and treatment of pelvic inflammatory disease. PID is an infection of the female reproductive organs, primarily the uterus, fallopian tubes, and ovaries, usually caused by sexually transmitted bacteria.

Here are some key factors driving the growth of the global PID treatment market:
High prevalence of pelvic inflammatory disease: Pelvic inflammatory disease is a common gynecological infection, particularly among sexually active women. The incidence of PID continues to rise globally, driving the demand for effective treatment options. Factors such as unsafe sexual practices, multiple sexual partners, and lack of awareness contribute to the high prevalence of PID.

Increasing awareness and early diagnosis: There is a growing emphasis on early diagnosis and prompt treatment of pelvic inflammatory disease to prevent complications and long-term reproductive health issues. Healthcare campaigns, educational initiatives, and improved access to healthcare services contribute to increased awareness and early detection of PID, positively impacting the treatment market.

Rising rates of sexually transmitted infections: Pelvic inflammatory disease is often a complication of sexually transmitted infections (STIs) such as chlamydia and gonorrhea. The global increase in the incidence of STIs, particularly among young adults, fuels the demand for PID treatment. Combatting the spread of STIs remains a priority for public health organizations, stimulating the market growth.

Technological advancements: Advances in medical technology and diagnostic techniques facilitate early and accurate diagnosis of PID. Modern imaging modalities, such as ultrasound and laparoscopy, aid in identifying the extent of infection and guide treatment decisions. Additionally, the development of novel therapeutics and treatment approaches contributes to market growth.

Development of effective treatment options: The pharmaceutical industry continues to invest in research and development activities focused on developing new and effective treatment options for PID. Antibiotics are the primary mode of treatment for PID, and efforts to improve their efficacy, reduce antibiotic resistance, and explore alternative therapies drive market growth.

Government initiatives and healthcare policies: Governments and healthcare organizations worldwide are implementing initiatives to address the burden of sexually transmitted infections and related complications, including PID. These initiatives include awareness campaigns, routine STI screening, accessible healthcare services, and subsidized or free treatment options. Supportive healthcare policies create a favorable environment for market growth.

In summary, the global pelvic inflammatory disease (PID) treatment market is driven by factors such as the high prevalence of PID, increasing awareness and early diagnosis, rising rates of sexually transmitted infections, technological advancements, development of effective treatment options, and government initiatives. As efforts to diagnose and treat PID improve, and with the focus on reducing complications and improving reproductive health outcomes, the global PID treatment market is expected to grow in the coming years.

Several types of antibiotics can cure PID. Antibiotic treatment does not, however, reverse any scarring caused by the infection. For this reason, it is critical that a woman receive care immediately if she has pelvic pain or other symptoms of PID. Prompt antibiotic treatment can prevent severe damage to the reproductive organs. The longer a woman delays treatment for PID, the more likely she is to become infertile or to have a future ectopic pregnancy because of damage to the fallopian tubes.

This report studies the global Pelvic Inflammatory Disease (PID) Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Pelvic Inflammatory Disease (PID) Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Pelvic Inflammatory Disease (PID) Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Pelvic Inflammatory Disease (PID) Treatment total market, 2018-2029, (USD Million)
Global Pelvic Inflammatory Disease (PID) Treatment total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Pelvic Inflammatory Disease (PID) Treatment total market, key domestic companies and share, (USD Million)
Global Pelvic Inflammatory Disease (PID) Treatment revenue by player and market share 2018-2023, (USD Million)
Global Pelvic Inflammatory Disease (PID) Treatment total market by Type, CAGR, 2018-2029, (USD Million)
Global Pelvic Inflammatory Disease (PID) Treatment total market by Application, CAGR, 2018-2029, (USD Million).

This reports profiles major players in the global Pelvic Inflammatory Disease (PID) Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Pfizer Inc., Lupin, Cambrex Corporation, Cipla Inc., Bayer AG, Daiichi Sankyo, Merck & Co., Inc and Allergan plc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Pelvic Inflammatory Disease (PID) Treatment market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Pelvic Inflammatory Disease (PID) Treatment Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Pelvic Inflammatory Disease (PID) Treatment Market, Segmentation by Type
Quinolones
Tetracycline
Beta-lactam
Nitroimidazoles
Others

Global Pelvic Inflammatory Disease (PID) Treatment Market, Segmentation by Application
Subacute Pelvic Inflammatory Disease
Chronic Pelvic Inflammatory Disease
Sexually Transmitted Pelvic Inflammatory Disease
Others

Companies Profiled:
Roche Holding AG
Pfizer Inc.
Lupin
Cambrex Corporation
Cipla Inc.
Bayer AG
Daiichi Sankyo
Merck & Co., Inc
Allergan plc
Actavis, Inc
Novartis A

Key Questions Answered
1. How big is the global Pelvic Inflammatory Disease (PID) Treatment market?
2. What is the demand of the global Pelvic Inflammatory Disease (PID) Treatment market?
3. What is the year over year growth of the global Pelvic Inflammatory Disease (PID) Treatment market?
4. What is the total value of the global Pelvic Inflammatory Disease (PID) Treatment market?
5. Who are the major players in the global Pelvic Inflammatory Disease (PID) Treatment market?

Table of Contents

1 Supply Summary
    1.1 Pelvic Inflammatory Disease (PID) Treatment Introduction
    1.2 World Pelvic Inflammatory Disease (PID) Treatment Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Pelvic Inflammatory Disease (PID) Treatment Total Market by Region (by Headquarter Location)
        1.3.1 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.3 China Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.4 Europe Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.5 Japan Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.6 South Korea Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.7 ASEAN Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
        1.3.8 India Pelvic Inflammatory Disease (PID) Treatment Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Pelvic Inflammatory Disease (PID) Treatment Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Pelvic Inflammatory Disease (PID) Treatment Major Market Trends

2 Demand Summary
    2.1 World Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.2 World Pelvic Inflammatory Disease (PID) Treatment Consumption Value by Region
        2.2.1 World Pelvic Inflammatory Disease (PID) Treatment Consumption Value by Region (2018-2023)
        2.2.2 World Pelvic Inflammatory Disease (PID) Treatment Consumption Value Forecast by Region (2024-2029)
    2.3 United States Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.4 China Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.5 Europe Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.6 Japan Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.7 South Korea Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.8 ASEAN Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)
    2.9 India Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029)

3 World Pelvic Inflammatory Disease (PID) Treatment Companies Competitive Analysis
    3.1 World Pelvic Inflammatory Disease (PID) Treatment Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Pelvic Inflammatory Disease (PID) Treatment Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Pelvic Inflammatory Disease (PID) Treatment in 2022
        3.2.3 Global Concentration Ratios (CR8) for Pelvic Inflammatory Disease (PID) Treatment in 2022
    3.3 Pelvic Inflammatory Disease (PID) Treatment Company Evaluation Quadrant
    3.4 Pelvic Inflammatory Disease (PID) Treatment Market: Overall Company Footprint Analysis
        3.4.1 Pelvic Inflammatory Disease (PID) Treatment Market: Region Footprint
        3.4.2 Pelvic Inflammatory Disease (PID) Treatment Market: Company Product Type Footprint
        3.4.3 Pelvic Inflammatory Disease (PID) Treatment Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Pelvic Inflammatory Disease (PID) Treatment Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Pelvic Inflammatory Disease (PID) Treatment Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Pelvic Inflammatory Disease (PID) Treatment Consumption Value Comparison
        4.2.1 United States VS China: Pelvic Inflammatory Disease (PID) Treatment Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Pelvic Inflammatory Disease (PID) Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Pelvic Inflammatory Disease (PID) Treatment Companies and Market Share, 2018-2023
        4.3.1 United States Based Pelvic Inflammatory Disease (PID) Treatment Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023)
    4.4 China Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue and Market Share, 2018-2023
        4.4.1 China Based Pelvic Inflammatory Disease (PID) Treatment Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023)
    4.5 Rest of World Based Pelvic Inflammatory Disease (PID) Treatment Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Pelvic Inflammatory Disease (PID) Treatment Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Pelvic Inflammatory Disease (PID) Treatment Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Quinolones
        5.2.2 Tetracycline
        5.2.3 Beta-lactam
        5.2.4 Nitroimidazoles
        5.2.5 Others
    5.3 Market Segment by Type
        5.3.1 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type (2018-2023)
        5.3.2 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type (2024-2029)
        5.3.3 World Pelvic Inflammatory Disease (PID) Treatment Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Pelvic Inflammatory Disease (PID) Treatment Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Subacute Pelvic Inflammatory Disease
        6.2.2 Chronic Pelvic Inflammatory Disease
        6.2.3 Sexually Transmitted Pelvic Inflammatory Disease
        6.2.4 Others
        6.2.5 Others
    6.3 Market Segment by Application
        6.3.1 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2018-2023)
        6.3.2 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2024-2029)
        6.3.3 World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2018-2029)

7 Company Profiles
    7.1 Roche Holding AG
        7.1.1 Roche Holding AG Details
        7.1.2 Roche Holding AG Major Business
        7.1.3 Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.1.4 Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 Roche Holding AG Recent Developments/Updates
        7.1.6 Roche Holding AG Competitive Strengths & Weaknesses
    7.2 Pfizer Inc.
        7.2.1 Pfizer Inc. Details
        7.2.2 Pfizer Inc. Major Business
        7.2.3 Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.2.4 Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Pfizer Inc. Recent Developments/Updates
        7.2.6 Pfizer Inc. Competitive Strengths & Weaknesses
    7.3 Lupin
        7.3.1 Lupin Details
        7.3.2 Lupin Major Business
        7.3.3 Lupin Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.3.4 Lupin Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Lupin Recent Developments/Updates
        7.3.6 Lupin Competitive Strengths & Weaknesses
    7.4 Cambrex Corporation
        7.4.1 Cambrex Corporation Details
        7.4.2 Cambrex Corporation Major Business
        7.4.3 Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.4.4 Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Cambrex Corporation Recent Developments/Updates
        7.4.6 Cambrex Corporation Competitive Strengths & Weaknesses
    7.5 Cipla Inc.
        7.5.1 Cipla Inc. Details
        7.5.2 Cipla Inc. Major Business
        7.5.3 Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.5.4 Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Cipla Inc. Recent Developments/Updates
        7.5.6 Cipla Inc. Competitive Strengths & Weaknesses
    7.6 Bayer AG
        7.6.1 Bayer AG Details
        7.6.2 Bayer AG Major Business
        7.6.3 Bayer AG Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.6.4 Bayer AG Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 Bayer AG Recent Developments/Updates
        7.6.6 Bayer AG Competitive Strengths & Weaknesses
    7.7 Daiichi Sankyo
        7.7.1 Daiichi Sankyo Details
        7.7.2 Daiichi Sankyo Major Business
        7.7.3 Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.7.4 Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 Daiichi Sankyo Recent Developments/Updates
        7.7.6 Daiichi Sankyo Competitive Strengths & Weaknesses
    7.8 Merck & Co., Inc
        7.8.1 Merck & Co., Inc Details
        7.8.2 Merck & Co., Inc Major Business
        7.8.3 Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.8.4 Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Merck & Co., Inc Recent Developments/Updates
        7.8.6 Merck & Co., Inc Competitive Strengths & Weaknesses
    7.9 Allergan plc
        7.9.1 Allergan plc Details
        7.9.2 Allergan plc Major Business
        7.9.3 Allergan plc Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.9.4 Allergan plc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Allergan plc Recent Developments/Updates
        7.9.6 Allergan plc Competitive Strengths & Weaknesses
    7.10 Actavis, Inc
        7.10.1 Actavis, Inc Details
        7.10.2 Actavis, Inc Major Business
        7.10.3 Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.10.4 Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Actavis, Inc Recent Developments/Updates
        7.10.6 Actavis, Inc Competitive Strengths & Weaknesses
    7.11 Novartis A
        7.11.1 Novartis A Details
        7.11.2 Novartis A Major Business
        7.11.3 Novartis A Pelvic Inflammatory Disease (PID) Treatment Product and Services
        7.11.4 Novartis A Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Novartis A Recent Developments/Updates
        7.11.6 Novartis A Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Pelvic Inflammatory Disease (PID) Treatment Industry Chain
    8.2 Pelvic Inflammatory Disease (PID) Treatment Upstream Analysis
    8.3 Pelvic Inflammatory Disease (PID) Treatment Midstream Analysis
    8.4 Pelvic Inflammatory Disease (PID) Treatment Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Pelvic Inflammatory Disease (PID) Treatment Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Pelvic Inflammatory Disease (PID) Treatment Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Pelvic Inflammatory Disease (PID) Treatment Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Pelvic Inflammatory Disease (PID) Treatment Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Pelvic Inflammatory Disease (PID) Treatment Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Pelvic Inflammatory Disease (PID) Treatment Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Pelvic Inflammatory Disease (PID) Treatment Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Pelvic Inflammatory Disease (PID) Treatment Players in 2022
    Table 12. World Pelvic Inflammatory Disease (PID) Treatment Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Pelvic Inflammatory Disease (PID) Treatment Company Evaluation Quadrant
    Table 14. Head Office of Key Pelvic Inflammatory Disease (PID) Treatment Player
    Table 15. Pelvic Inflammatory Disease (PID) Treatment Market: Company Product Type Footprint
    Table 16. Pelvic Inflammatory Disease (PID) Treatment Market: Company Product Application Footprint
    Table 17. Pelvic Inflammatory Disease (PID) Treatment Mergers & Acquisitions Activity
    Table 18. United States VS China Pelvic Inflammatory Disease (PID) Treatment Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Pelvic Inflammatory Disease (PID) Treatment Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Pelvic Inflammatory Disease (PID) Treatment Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share (2018-2023)
    Table 23. China Based Pelvic Inflammatory Disease (PID) Treatment Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Pelvic Inflammatory Disease (PID) Treatment Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share (2018-2023)
    Table 29. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application (2024-2029) & (USD Million)
    Table 35. Roche Holding AG Basic Information, Area Served and Competitors
    Table 36. Roche Holding AG Major Business
    Table 37. Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 38. Roche Holding AG Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. Roche Holding AG Recent Developments/Updates
    Table 40. Roche Holding AG Competitive Strengths & Weaknesses
    Table 41. Pfizer Inc. Basic Information, Area Served and Competitors
    Table 42. Pfizer Inc. Major Business
    Table 43. Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 44. Pfizer Inc. Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Pfizer Inc. Recent Developments/Updates
    Table 46. Pfizer Inc. Competitive Strengths & Weaknesses
    Table 47. Lupin Basic Information, Area Served and Competitors
    Table 48. Lupin Major Business
    Table 49. Lupin Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 50. Lupin Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Lupin Recent Developments/Updates
    Table 52. Lupin Competitive Strengths & Weaknesses
    Table 53. Cambrex Corporation Basic Information, Area Served and Competitors
    Table 54. Cambrex Corporation Major Business
    Table 55. Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 56. Cambrex Corporation Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Cambrex Corporation Recent Developments/Updates
    Table 58. Cambrex Corporation Competitive Strengths & Weaknesses
    Table 59. Cipla Inc. Basic Information, Area Served and Competitors
    Table 60. Cipla Inc. Major Business
    Table 61. Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 62. Cipla Inc. Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Cipla Inc. Recent Developments/Updates
    Table 64. Cipla Inc. Competitive Strengths & Weaknesses
    Table 65. Bayer AG Basic Information, Area Served and Competitors
    Table 66. Bayer AG Major Business
    Table 67. Bayer AG Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 68. Bayer AG Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. Bayer AG Recent Developments/Updates
    Table 70. Bayer AG Competitive Strengths & Weaknesses
    Table 71. Daiichi Sankyo Basic Information, Area Served and Competitors
    Table 72. Daiichi Sankyo Major Business
    Table 73. Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 74. Daiichi Sankyo Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. Daiichi Sankyo Recent Developments/Updates
    Table 76. Daiichi Sankyo Competitive Strengths & Weaknesses
    Table 77. Merck & Co., Inc Basic Information, Area Served and Competitors
    Table 78. Merck & Co., Inc Major Business
    Table 79. Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 80. Merck & Co., Inc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Merck & Co., Inc Recent Developments/Updates
    Table 82. Merck & Co., Inc Competitive Strengths & Weaknesses
    Table 83. Allergan plc Basic Information, Area Served and Competitors
    Table 84. Allergan plc Major Business
    Table 85. Allergan plc Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 86. Allergan plc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Allergan plc Recent Developments/Updates
    Table 88. Allergan plc Competitive Strengths & Weaknesses
    Table 89. Actavis, Inc Basic Information, Area Served and Competitors
    Table 90. Actavis, Inc Major Business
    Table 91. Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 92. Actavis, Inc Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Actavis, Inc Recent Developments/Updates
    Table 94. Novartis A Basic Information, Area Served and Competitors
    Table 95. Novartis A Major Business
    Table 96. Novartis A Pelvic Inflammatory Disease (PID) Treatment Product and Services
    Table 97. Novartis A Pelvic Inflammatory Disease (PID) Treatment Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 98. Global Key Players of Pelvic Inflammatory Disease (PID) Treatment Upstream (Raw Materials)
    Table 99. Pelvic Inflammatory Disease (PID) Treatment Typical Customers
List of Figure
    Figure 1. Pelvic Inflammatory Disease (PID) Treatment Picture
    Figure 2. World Pelvic Inflammatory Disease (PID) Treatment Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Pelvic Inflammatory Disease (PID) Treatment Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Pelvic Inflammatory Disease (PID) Treatment Revenue (2018-2029) & (USD Million)
    Figure 13. Pelvic Inflammatory Disease (PID) Treatment Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Pelvic Inflammatory Disease (PID) Treatment Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Pelvic Inflammatory Disease (PID) Treatment Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Pelvic Inflammatory Disease (PID) Treatment by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Pelvic Inflammatory Disease (PID) Treatment Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Pelvic Inflammatory Disease (PID) Treatment Markets in 2022
    Figure 27. United States VS China: Pelvic Inflammatory Disease (PID) Treatment Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Pelvic Inflammatory Disease (PID) Treatment Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Pelvic Inflammatory Disease (PID) Treatment Market Size Market Share by Type in 2022
    Figure 31. Quinolones
    Figure 32. Tetracycline
    Figure 33. Beta-lactam
    Figure 34. Nitroimidazoles
    Figure 35. Others
    Figure 36. World Pelvic Inflammatory Disease (PID) Treatment Market Size Market Share by Type (2018-2029)
    Figure 37. World Pelvic Inflammatory Disease (PID) Treatment Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 38. World Pelvic Inflammatory Disease (PID) Treatment Market Size Market Share by Application in 2022
    Figure 39. Subacute Pelvic Inflammatory Disease
    Figure 40. Chronic Pelvic Inflammatory Disease
    Figure 41. Sexually Transmitted Pelvic Inflammatory Disease
    Figure 42. Others
    Figure 43. Pelvic Inflammatory Disease (PID) Treatment Industrial Chain
    Figure 44. Methodology
    Figure 45. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Roche Holding AG
Pfizer Inc.
Lupin
Cambrex Corporation
Cipla Inc.
Bayer AG
Daiichi Sankyo
Merck & Co., Inc
Allergan plc
Actavis, Inc
Novartis A

Related Reports

Global Pelvic Inflammatory Disease (PID) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Pelvic Inflammatory Disease (PID) Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 02 Sep 2023

date Medical Care

According to our (Global Info Research) latest study, the global Pelvic Inflammatory Disease (PID) Treatment market size was valued at USD 774.8 million in 2022 and is forecast to a readjusted size of USD 1120.9 million by 2029 with a CAGR of 5.4% during review period.

Global Pelvic Inflammatory Disease (PID) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Pelvic Inflammatory Disease (PID) Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 10 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Pelvic Inflammatory Disease (PID) Treatment market size was valued at USD 774.8 million in 2023 and is forecast to a readjusted size of USD 1120.9 million by 2030 with a CAGR of 5.4% during review period.

Product Tags

pelvic inflammatory disease pid treatment

Pelvic Inflammatory Disease (PID) Treatment

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>